Select Page

South Delhi Pharma, New Delhi, India

REVLIMID [lenalidomide] capsules, for oral use.

Under Named Patient Supply, SDP serve you through the quality pharmaceutical products as per your needs. Established in the year 1996. SDP have earned global reputation in the market and has widest range of Anti Cancer medicines in India. To get the best price/cost of medicines in India, Call 9891296838 or Email query@southdelhipharma.com to discuss.

REVLIMID is a prescription medicine. REVLIMID is used to treat multiple myeloma.
INDICATIONS AND USAGE
REVLIMID is a thalidomide analogue indicated for the treatment of patients with:
• Multiple myeloma (MM), in combination with dexamethasone, in patients who have received at least one prior therapy.
• Transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q abnormality with or without additional cytogenetic abnormalities.
• Mantle cell lymphoma (MCL) whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib
DOSAGE FORMS & STRENGTHS
Capsules: 2.5 mg, 5 mg, 10 mg, 15 mg, 20 mg, and 25 mg
Manufactured By: Celgene Corporation
Prescribing Information URL: Click Here

South Delhi Pharma can facilitate the supply of “REVLIMID [lenalidomide] capsules” to all locations in India and other part of countries after fulfilling the legal requirement (if applicable). All Anticancer drugs available upon request. To get best price please share your mobile number to receive quotes from South Delhi Pharma.

Category:

Get In Touch

Get in touch with us at South Delhi Pharma (SDP), and one of our team will be on hand to help with any queries you may have.

The SDM is open
Monday to Friday.
Business hours: 09:30 A.M to 18:30 P.M.

Contact Number:
M:+91-9891296838 / P:+91-11- 26532129

Email ID:
info@southdelhipharma.com

Lenalidomide, sold under the trade name Revlimid among others, is a medication used to treat multiple myeloma (MM) and myelodysplastic syndromes (MDS). For MM it is used after at least one other treatment and generally together with dexamethasone.

Lenalidomide was approved for medical use in the United States in 2005. It is on the World Health Organization's List of Essential Medicines.

In 2006, lenalidomide received U.S. Food and Drug Administration (FDA) clearance for use in combination with dexamethasone in people with multiple myeloma who have received at least one prior therapy. In 2017, the FDA approved lenalidomide as standalone maintenance therapy (without dexamethasone) for people with multiple myeloma following autologous stem cell transplant.

In 2009, The National Institute for Health and Clinical Excellence issued a final appraisal determination approving lenalidomide in combination with dexamethasone as an option to treat people with multiple myeloma who have received two or more prior therapies in England and Wales.

The use of lenalidomide combined with other drugs was evaluated. It was seen that the drug combinations of lenalidomide plus dexamethasone and continuous bortezomib plus lenalidomide plus dexamethasone probably result in an increase of the overall survival.

1 review for REVLIMID [lenalidomide] capsules, for oral use.

  1. visit this web-site

    I was reading some of your articles on this site and I conceive this internet site is real instructive! Continue posting.

    https://shannontaxi.eu

Add a review

Your email address will not be published.